Activin inhibition of prostate cancer cell growth: Selective actions on androgen-responsive LNCaP cells

Endocrinology

Volumn 137, Issue 12, 1996, Pages 5230-5235

  Dalkin, A C ^a   Gilrain, J T ^a   Bradshaw, D ^b   Myers, C E ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ANDROGEN; FOLLISTATIN; FOLLITROPIN; LUCIFERASE; MESSENGER RNA; PEPTIDE; RECEPTOR; RECEPTOR SUBUNIT; RECOMBINANT ACTIVIN; STEROID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030460696     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.12.8940339     Document Type: Article

References (41)

1. Ying S-Y 1988 Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9:267-293
2. DePaolo LV, Bicsak TA, Erikson GF, Shimasaki S, Ling N 1991 Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc Soc Exp Biol Med 198:500-512
3. Mathews L 1994 Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310-325
4. Esch FS, Shimasaki S, Mercado M, Cooksey K, Ling N, Ying S, Ueno N, Guillemin R 1987 Structure and characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol 1:849-855
5. Robertson DM, Klein R, de Vos FL, McLachlan RI, Wettenhall REH, Hearn MTW, Burger HG, de Kretser DM 1987 The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 149:744-749
6. Michel U, Albiston A, Findlay JK 1990 Rat follistatin: gonadal and extragonadal expression and evidence for alternative splicing. Biochem Biophys Res Commun 173:401-407
7. Kogawa K, Nakamura T, Sugino K, Takio K, Titani K, Sugino H 1991 Activin-binding protein is present in pituitary. Endocrinology 128:1434-1440
8. van den Eijnden-van Raaij AJM, Feijen A, Lawson KA, Mummery CL 1992 Differential expression of inhibin subunits and follistatin, but not activin receptor type II during early murine embryonic development. Dev Biol 154:356-365
9. Roberts VJ, Barth SL 1994 Expression of mRNAs encoding the inhibin/activin system during mid- and late-gestation rat embryogenesis. Endocrinology 134:914-921
10. Feng Z-M, Madigan MB, Chen C-LC 1993 Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology 132:2593-2600
11. Kyprianou N, Isaacs JT 1989 Expression of transforming growth facror-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522
12. Kyprianou N, Isaacs JT 1988 Identification of a cellular receptor for transforming growth factor-β in the rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131
13. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Sensibar JA, Kim J-H, Kato M, Lee C 1996 Genetic change in transforming growth factor β(TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 56:44-48
14. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E 1989 Differential effects of transforming growth factor-β on human prostate cancer cells in vitro. Mol Cell Endocrinol 62:79-87
15. Kim IY, Zelner DJ, Sensibar JA, Ahn H-J, Park L, Kim J-H, Lee C 1996 Modulation of sensitivity to transforming growth factor-β1 (TGF-β1) and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res 222:103-110
16. Steiner MS, Barrack ER 1992 Transforming growth factor β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25
17. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH 1993 Transgenic models for the study of prostate cancer. Cancer 71:1165-1171
18. McKeehan WL, Adams PS, Rosser MP 1984 Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 44:1998-2010
19. Zhang Z, Ying C, Batres Y, Furst B, Xing WX, Ying SY, Expression of activin and activin receptors in the prostate cancer cell lines LNCaP and DU-145. 77th Annual Meeting of The Endocrine Society, Washington DC, 1995 (Abstract P1-363)
20. Dalkin AC, Gilrain JT, Marshall JC 1994 Ovarian regulation of pituitary inhibin subunit and activin receptor type II gene expression: evidence for a nonsteroidal inhibitory substance. Endocrinology 135:944-949
21. Papavasiliou SS, Zmeili S, Herbon L, Duncan-Weldon J, Marshall JC, Landefeld TD 1986 Q and LHβ mRNA quantitation in the anterior pituitary of castrate male and female rats using an optimized RNA dot blot hybridization assay. Endocrinology 119:691-698
22. Castro MG, Tomasec P, Morrison E, Murray CA, Hodge P, Blanning P, Linteon E, Lowry PJ, Lowensteein PR 1995 Mitogenic effects and nuclear localization of procorticotrophin-releasing hormone expressed with stably transfected fibroblast cells (CHO-K1). Mol Cell Endocrinol 107:17-25
23. 3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods 187:85-93
24. Kim H, Lee HS, Chang KT, Ko TH, Baek KJ, Kwon SK 1995 Chloromethyl ketones block induction of nitricoxide synthase in murine macrophages by preventing activation of nuclear factor-κB. J Immunol 154:4741-4748
25. Shimasaki S, Koga M, Esch F, Ueno N, Ying S-Y, Ling N, Guillemin R 1988 Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA 85:4218-4222
26. Shimasaki S, Koga M, Buscaglia ML, Simmons DM, Bicsak TA, Ling N 1989 Follistatin gene expression in the ovary and extragonadal tissues. Mol Endocrinol 3:651-659
27. McCarthy SA, Bicknell R 1993 Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268:23066-23071
28. Gonzalez-Manchon C, Vale W 1993 Activin-A, inhibin and transforming growth factor-β modulate growth of two gonadal cell lines. Endocrinology 125:1666-1672
29. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG 1993 Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18:347-356
30. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, Kojima I 1993 Activin-A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 92:1491-1496
31. Yu J, Shao L, Vaughan J, Vale W, Yu AL 1989 Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 72:952-960
32. Shiozaki M, Sakai R, Tabuchi M, Eto Y, Kosaka M, Shibai H 1989 In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochem Biophys Res Commun 165:1155-1161
33. Matzuk MM, Finegold MJ, Jyan-Gwo JS, Hsueh AJW, Bradley A 1992 α-Inhibin is a tumor-suppresser gene with gonadal specificity in mice. Nature 360:313-319
34. Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJW 1994 Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-α and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol 8:983-995
35. Kananen K, Markkula M, Rainio E, Su J-G J, Hsueh AJW, Huhtaniemi IT 1995 Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin α-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol 9:616-627
36. Kim IY, Zelner DJ, Sensibar JA, Ahn H-J, Park L, Kim J-H, Lee C 1996 Modulation of sensitivity to transforming growth factor-β1 (TGF-β1) and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res 222:103-110
37. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF 1994 Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology 135:667-674
38. Krummen LA, Woodruff TK, DeGuzman G, Cox ET, Baly DL, Mann E, Garg S, Wong WL, Cossum P, Mather JP 1993 Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology 132:431-434
39. Grayhack JT, Lee C, Brand W 1985 The effect of testicular irradiation on established BPH in the dog: evidence of a non-steroidal testicular factor for BPH maintenance. J Urol 134:1276-1281
40. Wrana JL, Attisano L, Carcamo J, Zentell A, Doody J, Laiho M, Wang X, Massague J 1992 TGF-β signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014
41. Wang QF, Schneyer AL, Crowley WF, Sluss PM, Overexpression of follistatin by a human prostate cancer cell line, PC-3. 10th International Congress of Endocrinology, San Francisco CA, 1996, p 823 (Abstract P3-276)